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SUMMARY
Identification of the correct etiology of diabetes brings important implications for clinical management. 
In this report, we describe a case of a 4-year old asymptomatic girl with diabetes since age 2, along 
with several individuals in her family with different etiologies for hyperglycemia identified in youth. 
Genetic analyses were made by Sanger sequencing, laboratory measurements included HbA1c, 
lipid profile, fasting C-peptide, pancreatic auto-antibodies (glutamic acid decarboxylase [GAD], Islet 
Antigen 2 [IA-2], and anti-insulin). We found a Gly178Ala substitution in exon 5 of GCK gene in three 
individuals co-segregating with diabetes, and type 1 diabetes was identified in two other individuals 
based on clinical and laboratory data. One individual with previous gestational diabetes and other 
with prediabetes were also described. We discuss difficulties in defining etiology of hyperglycemia 
in youth in clinical practice, especially monogenic forms of diabetes, in spite of the availability of 
several genetic, laboratory, and clinical tools. Arch Endocrinol Metab. 2017;61(6):637-42
INTRODUCTION
I dentification of the exact etiology of diabetes brings important implications for clinical management, 
therapeutic choice, medical follow-up, screening of 
clinical complications, and prognosis, as well as genetic 
counseling when applicable.
Currently, in addition to more common forms such 
as type 1 and type 2 diabetes, molecular diagnosis of 
monogenic forms of diabetes has gained momentum 
due to the ever growing availability of centers 
performing genetic testing. In this report, we describe 
a family in whom several different types of diabetes have 
been diagnosed, underscoring the caveats of correctly 
identifying the etiology of diabetes.
FAMILY PRESENTATION
The proband is a 4-year old asymptomatic girl (subject 
21 on the pedigree chart, Figure 1), who was diagnosed 
with hyperglycemia in a routine visit with a pediatrician 
(fasting plasma glucose [FPG] 6.43 mmol/L) when 
she was 2 years old. Her current weight is 17 kg and 
height is 98 cm. She was a full-term newborn (birth 
weight 2450 g) with healthy neuropsychomotor 
development. Further glucose testing showed FPG 
6.21 mmol/L, hemoglobin A1c (HbA1c) 6%, 
C-peptide 0.67 ng/mL, and negative pancreatic auto-
antibodies (glutamic acid decarboxylase [GAD], Islet 
Antigen 2 [IA-2], and anti-insulin all below detection 
threshold for each assay). Her mother (subject 19) 
had had a previous history of gestational diabetes at 
age 30, identified at 25 weeks gestational age, with 
progression to normoglycemia after pregnancy. Her 
father (subject 18) has shown hyperglycemia since 
age 20 without any symptoms or medication use. Her 
paternal grandfather (subject 9) was diagnosed with 
diabetes at age 20 and has been on insulin treatment 
since then; his monozygotic twin (subject 8) presented 
with prediabetes years ago, without specific treatment. 
Also, on the paternal side of the family, there is a 
41-year old second cousin (subject 14), who was 
diagnosed with diabetes at age 8, also in use of insulin. 
Her paternal grandmother (subjected 10) is 57 years 
old with a history of hyperglycemia since 22 years old, 
identified in a routine scan, as part of a pre-employment 
assessment. She is asymptomatic, in use of metformin. 
Table 1 summarizes the main clinical and laboratory 
characteristics of family members.
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NN: normal-normal; NM: normal-mutated; regarding GCK Gly178Ala substitution. Normal type numbers refers to consecutive patient numbering as described in the text. Bold type numbers enclosed 
in borders describe age at diagnosis. The arrow indicates the proband. Individuals 10, 18, and 21 are GCK-MODY; individuals 9 and 14 have type 1 diabetes; individuals 8 has prediabetes; individual 
19 has previous gestational diabetes.
Figure 1. Pedigree of the studied family. Hyperglycemic and normoglycemic individuals depicted as black and white circles/squares, respectively.
Table 1. Clinical characteristics of studied individuals
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7 Normoglycemic F 67 NA 25 - - 4.9 5.5 / 37 NT NT 5.4 3.4 1.5 1.2 0.9 None
8 Prediabetes M 66 NA 25.4 + + 6.0 5.8 / 40 6.9 - 5.3 3.4 1.3 1.2 1.0 Diet
9 Type 1 diabetes M 66 20 28.7 + + 12.4 6.3 / 45 < 0.1 - 3.7 1.9 1.5 0.5 0.9 NPH + Lispro
10 GCK-MODY F 57 22 23.8 - - 6.4 6.6 / 49 1.1 - 6.2 4.1 1.8 0.5 0.6 Metformin
11 Normoglycemic M 55 NA 28.1 + + 4.9 5.7 / 39 NT - 6.2 3.9 1.0 2.8 1.0 None
14 Type 1 diabetes M 41 8 32.8 - - 11.4 6.4 / 46 < 0.1 IA2 + 4.1 2.3 1.6 0.6 0.8 NPH + Lispro insulin
15 Normoglycemic F 37 NA 21.1 - - 4.2 4.8 / 29 NT NT 3.9 1.9 1.8 0.4 0.7 None
16 Normoglycemic M 35 NA 32.4 - - 5.3 5.5 / 37 3.8 - 5.1 3.3 1.1 1.4 1.1 None
17 Normoglycemic M 26 NA 26.9 - - 5.1 6.1 / 36 NT - 4.3 2.8 1.1 0.9 0.9 None
18 GCK-MODY M 30 20 27.2 - - 7.2 6.1 / 43 1.1 - 4.6 2.9 1.3 0.5 0.9 None
19 Previous GDM F 34 NA 24.5 - - 5.0 5.6 / 38 NT - 5.6 3.8 1.4 0.9 0.7 None
20 Normoglycemic F 28 NA 21.7 - - 5.0 4.7 / 28 NT NT 4.3 2.4 1.7 0.6 0.8 None
21 GCK-MODY F 4 2 * - - 6.2 6.0 / 42 0.67 - 4.0 2.4 1.1 1.1 0.6 Diet
GDM: gestational diabetes mellitus; F: female; M: male; NA: not applicable; NT: not tested; * BMI was not calculated due to age, please see text for weight and height data. Proband data (subject 
21) in boldtype. To convert total cholesterol, HDL-cholesterol, and LDL-cholesterol to mg/dL, divide values by 0.0259; to convert triglycerides to mg/dL, divide values by 0.0113; to convert glucose 
to mg/dL, divide values by 0.0555.
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The atypical clinical presentation of hyperglycemia 
in the proband, along with her family background and 
absence of immunologic markers specific for type 1 
diabetes, raised the hypothesis of monogenic diabetes – 
more specifically Maturity-Onset Diabetes of the Young 
(MODY) caused by a glucokinase (GCK) mutation. 
Genetic testing showed a Gly178Ala substitution in 
exon 5. The same mutation was found in the proband’s 
father (subject 18) and paternal grandmother (subject 
10), and is depicted in Figure 1 as normal-mutated (NM) 
to demonstrate its heterozygous pattern. Her mother, 
paternal grandfather, grandfathers’s twin brother, two 
second cousins, and normoglycemic uncles (subjects 8, 
9, 11, 14, 17, 19, and 20) did not presented any GCK 
mutations and are depicted as normal-normal (NN). 
The clear co-segregation of the mutation with mild 
non-progressive hyperglycemia strongly suggests it to 
have a causal effect (Figure 1). This mutation has been 
described for the first time in medical literature in this 
family. It was reported briefly in a recent publication 
by the Brazilian Monogenic Diabetes Study Group 
(BRASMOD), a multicenter group of researchers in the 
field of Monogenic Diabetes (1), but personal clinical 
data are presented here for the first time.
METHODS
GCK, HNF1A, and HNF4A genes were analyzed by 
Sanger sequencing, using previously described primers 
and parameters (2). Pathogenicity of mutations was 
assessed by the American College of Medical Genetics 
and Genomics (ACMG) guidelines (3). HNF1B 
genotyping was performed with previously described 
methods (4). Hemoglobin A1c (HbA1c) was analyzed by 
High-Performance Liquid Chromatography (HPLC). 
C-peptide was analyzed by chemiluminometric assay. 
GAD antibodies have been assessed by enzyme-linked 
immunosorbent assay (ELISA); IA-2 and anti-insulin 
autoantibodies were assessed by radioimmunoassay. 
Diabetes and prediabetes were diagnosed according to 
the American Diabetes Association criteria (5). Arterial 
hypertension was defined as systolic blood pressure 
(SBP) ≥ 140 mmHg and/or diastolic blood pressure 
(DBP) ≥ 90 mmHg, or current use of antihypertensive 
medication and history of hypertension (6). Subjects 
were considered to have dyslipidemia either if 
levels of LDL-cholesterol were ≥ 4.14 mmol/L, 
HDL-cholesterol ≤ 1.04 mmol/L, triglycerides 
≥ 2.26 mmol/L, or if they were using lipid lowering 
medications (statin/fibrates) (6). The remaining clinical 
and laboratory data were collected from each patient’s 
medical records. All patients or relatives responsible 
for the patients have provided informed consent, with 
approval by Hospital São Paulo’s Ethics Committee.
DISCUSSION
In this article we have described a family with multiple 
types of diabetes/hyperglycemia, diagnosed in infancy 
or early adulthood, underscoring the issue of etiological 
definition of diabetes in this age group, commonly 
dealt with in clinical practice. As far as we know, this is 
the first Brazilian report with these features.
The correct differentiation of monogenic forms 
from type 1 diabetes has significant clinical impact in 
treating the two most important differential diagnoses. 
Some subtypes of monogenic diabetes can be treated 
with sulfonylureas, like those caused by mutations 
in genes such as HNF1A and HNF4A (7), whereas 
others such as GCK-MODY may not need medical 
treatment at all (8). This is in contrast with type 1 
diabetes, in which insulin therapy is required. A correct 
definition of diabetes etiology is often challenging, 
despite the availability of biochemical tests, pancreatic 
autoantibodies assessment, and molecular biology tools. 
In this regard, Patel and cols., in the United Kingdom, 
have recently proposed a genetic score with 30 variants 
to stratify the risk of development of type 1 diabetes. 
The study has suggested that the genetic score has 
shown good discriminative power to distinguish type 
1 diabetes from monogenic forms (9) and in another 
analysis, the score was also useful to differentiate young 
type 2 diabetes (10). A meta-analysis by the same group 
assessed which clinical parameters could be relevant in 
the etiological differential diagnosis of the many types 
of diabetes. Age at diagnosis (< 35 years) and the period 
for insulin requirement (until 6 months after diagnosis) 
seem to be useful in distinguishing between type 1 and 
type 2 diabetes (11).
In this context, the use of biochemical markers 
could also be important. C-peptide is produced in 
concentrations equimolar to insulin and thus correlates 
with pancreatic residual function. C-peptide is more 
helpful 3 to 5 years after diagnosis, when its persistence 
may indicate type 2 diabetes or monogenic diabetes. 
Besides, undetectable levels at anytime in disease 
progression suggest type 1 diabetes. Normal reference 
values of C-peptide are variable in literature, but fasting 
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C-peptide < 0.6 ng/mL usually indicates marked 
impairment of beta-cell function (12). C-peptide can 
be measured either in fasting or after a stimulus (with 
a mixed meal or glucagon) to detect beta-cell residual 
function. Some authors showed that urinary C-peptide-
creatinine ratio (UCPCR) is a useful alternative method 
to measure C-peptide that can discriminate HNF1A/
HNF4A MODY from long-duration type 1 diabetes, 
although this test is not routinely performed in our 
clinic (13). In the present family all GCK-MODY 
subjects presented fasting C-peptide above 0.6 ng/mL, 
while those with type 1 diabetes (either confirmed 
by detection of autoantibodies or not) showed 
undetectable values (Table 1), suggesting it as a good 
discriminator between both diabetes subtypes.
Current methods of genetic tests for MODY 
mutations are expensive and time consuming. Patients 
should be carefully selected by clinical criteria for 
testing, as this can significantly increase the positivity 
detection rate (14). In order to enhance accuracy in 
the recruitment of suspected cases of MODY, a team of 
researchers developed software based in specific clinical 
data that calculates the patient’s probability of having 
a positive molecular test for MODY mutations. This 
software uses data such as age, insulin requirement 
within 6 months after diagnosis, and familial history 
of diabetes. Moving on to genetic testing is suggested 
when the score is greater than 25% (15). Of note, all 
patients with GCK-MODY in the present family had a 
score above this cutoff point (data not shown). Other 
strategies for patient selection and mutation screening 
have been proposed. Shepherd and cols., investigating 
the prevalence of monogenic diabetes in U.K. pediatric 
clinics in patients younger than 20 years old, used a 
systematic approach of biomarker screening with 
UCPCR, islet autoantibodies (GAD and IA-2), and 
targeted genetic testing. They found 2.5% of patients to 
have monogenic diabetes. Authors suggested that this 
biomarker screening algorithm could be a rational and 
practical approach to identifying pediatric patients who 
are most suitable for genetic testing (16).
Therefore, an attempt for establishing diagnosis or 
rendering a provisional etiology in each case is discussed 
as follows.
The proband (subject 21) had a typical clinical 
presentation of GCK-MODY with mild hyperglycemia 
and no symptoms, along with classic laboratory 
findings like detectable levels of C-peptide and absence 
of pancreatic auto-immunity. This raises the question 
of which parent she has inherited her mutation from. 
If on the one hand her mother (subject 19) had 
previous gestational diabetes, on the other hand, her 
father (subject 18) has also had mild non-progressive 
hyperglycemia for several years. Her father also showed 
a clinical pattern of GCK-MODY, being diagnosed at 
age 20 without clinical manifestations. 
The proband’s mother, previously normoglycemic, 
had had a history of gestational diabetes identified at 
25 weeks of pregnancy. Her oral glucose tolerance test 
[OGTT] showed glucose values of 4.2, 9.2, and 9.1 
mmol/L in fasting, at 1, and 2 hours, respectively (5), 
and she was managed only with diet. After delivery, 
blood glucose returned to normal levels as shown by 
a further OGTT. She was unaware of any other cases 
of diabetes in her family. The inherited mutation could 
have reflected on birthweight, partially explaining why 
macrosomia did not occur (17). Several studies show 
that weight of children born with GCK mutations is 
usually ~700g lower compared to siblings who did not 
inherited the mutation. This finding is more robust when 
the mother also shows hyperglycemia caused by a GCK 
mutation, but it could be extrapolated to the gestational 
diabetes context. This is possibly due to lower insulin 
secretion during intrauterine life (18). Her paternal 
grandmother (subject 10) had a typical presentation of 
GCK-MODY with mild non-progressive asymptomatic 
hyperglycemia, identified in routine pre-employment 
testing when she was 22. Genetic testing successfully 
confirmed the GCK mutation in the grandmother and 
ruled it out in the grandfather, in whom clinical features 
are more resemblant of other forms of hyperglycemia. 
Besides typical clinical GCK-MODY presentation and 
familial cosegregation, Gly178Ala mutation is Likely 
Pathogenic according to ACMG guidelines, presenting 
2 Moderate Criteria and 3 Supporting Criteria (3). 
Besides, this variant has not been found in population 
databases of exome sequences (19).
While the proband’s paternal grandfather (subject 9) 
has a history of diabetes since his early youth, his 
monozygotic twin brother (subject 8) shows a 
prediabetes pattern that could resemble GCK-MODY 
(see below). He could have inherited not only the 
GCK-MODY mutation but also genetic predisposition 
to type 1 diabetes, which would hypothetically result in 
a more severe clinical presentation prevailing, but this 
was not the case as demonstrated by negative genetic 
testing in him. Furthermore, he had a history of diabetes 
diagnosed at age 20, presenting with polydipsia, 
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requiring insulin since diagnosis, and showing 
undetectable levels of C-peptide. Thus a diagnosis of 
type 1 diabetes is strongly suggested. Negative GAD 
and IA-2 antibodies could simply reflect long disease 
duration, with the reduction of antibody titers that 
is usually observed in type 1 diabetes. A more rare 
condition could be the presence of an HNF1A or even 
HNF4A mutation in subject 9 and his twin brother with 
prediabetes. HNF1A-MODY presents mostly as overt 
diabetes, a phenotype markedly different from GCK-
MODY. Genetic testing for these MODY-subtypes has 
been carried out in subject 9 with negative results. Co-
existence of different MODY subtypes (HNF1A and 
GCK) has been described in a family in whom clinical 
predominance of the most severe subtype, i.e. HNF1A, 
occurred. A targeted NGS panel with several MODY 
genes could be an important tool in such cases (20,21).
An interesting feature of subject 9 is the presence of 
persistent proteinuria and hematuria, but with a normal 
retinal examination, together with normal creatinine 
clearance (102 mL/min/m2) and normal urinary tract 
ultrasound. This finding could suggest etiologies other 
than diabetes for nephropathy (22). Type 2 diabetes 
could be considered, but insulin requirement being 
present since diagnosis undermines this hypothesis. 
His twin brother (subject 8) presents with prediabetes 
diagnosed both by fasting glucose and HbA1c several 
years ago (approximately 10 years). No pancreatic 
autoimmunity has been demonstrated. This individual 
(subject 8) could either have type 2 diabetes-related 
prediabetes or preclinical type 1 diabetes. The absence 
of autoimmunity balances the scale toward the first 
hypothesis. Like his brother he has also presented with 
hematuria for several years and persistent proteinuria 
(around 0.85 g/L), renal cysts at ultrasound, and 
stable creatinine clearance over the last few years 
(ranging from 90 to 110 mL/min). One hypothesis 
for explaining the etiology of hyperglycemia with renal 
alterations, especially renal cysts, could be an HNF1B 
mutation, which has also been tested with negative 
results, consequently excluding this MODY subtype 
also in his twin brother (4,23).
On the paternal grandfather’s side of the family, there 
is a 41-year old second-cousin (subject 14) without 
diabetic complications and a typical type 1 diabetes 
presentation, i.e., diagnosis at age 8, insulin treatment 
since then, and undetectable C-peptide. DKA was seen 
upon diagnosis and other episodes occurred during 
his life as well. GAD65 autoantibodies were negative 
(< 0.5 UI/mL), but IA-2 was positive (1.2 U/mL; 
normal range < 0.8 U/mL), strongly suggesting type 1A 
diabetes, thus the most likely etiology in this individual 
is autoimmune. 
CONCLUSION
Abnormal glucose levels are the common element 
present in different diseases such as GCK-MODY, 
prediabetes, type 1 diabetes, and gestational diabetes, 
especially in children, teenagers, and young adults. 
As a consequence, it can be challenging to correctly 
define a precise diabetes etiology. Improvement in 
the understanding of diabetes depends on thorough 
analysis of clinical data, genetic testing, and laboratory 
findings. Despite all recent advancements in molecular 
diagnosis, the definition of a clinical screening model 
for monogenic diabetes is still a challenge that demands 
the systematic study of several families in different 
populations. In conclusion, the accurate molecular 
and clinical diagnosis has significant impact on clinical 
management of a multifaceted disease such as diabetes, 
especially when running on the same family.
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